LLY - Lilly Incyte's baricitinib reduces deaths among COVID-19 patients on mechanical ventilation

Eli Lilly (NYSE:LLY) and Incyte (NASDAQ:INCY) announce results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with COVID-19 on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) who received baricitinib plus standard of care were 46% less likely to die by Day 28 compared to patients who received placebo plus standard of care (nominal p-value=0.0296; hazard ratio [HR] [95% CI] = 0.54 [0.31, 0.96]). The cumulative proportion of patients who died by Day 28 was 39.2% in the baricitinib arm vs. 58% in placebo arm. Similar mortality benefit was observed by Day 60 (HR [96% CI] = 0.56 [0.33, 0.97]) with cumulative proportion of death of 45.1% for baricitinib compared to 62.0% for placebo. These findings are consistent with the reduction in mortality observed in the overall COV-BARRIER patient population. Venous thromboembolic events were reported in 6% of baricitinib-treated patients and 6.1% of

For further details see:

Lilly, Incyte's baricitinib reduces deaths among COVID-19 patients on mechanical ventilation